Brexpiprazole
Brexpiprazole is an atypical antipsychotic. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A receptors. This modulating activity helps balance dopamine and serotonin levels in the brain to improve thinking, mood, and behavior.
Dosage by Body Weight
Take orally once daily, with or without food. For Major Depressive Disorder (adjunctive): Start at 0.5 mg or 1 mg daily, titrate up to a target dose of 2 mg daily. For Schizophrenia: Start at 1 mg daily, titrate up to a target dose of 2 mg to 4 mg daily. For Alzheimer's agitation: Start at 0.5 mg daily, titrate up to a target dose of 2 mg daily.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brexpiprazole is not approved for use in pediatric patients or dosed by body weight.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brexpiprazole is not approved for use in pediatric patients or dosed by body weight.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brexpiprazole is not approved for use in pediatric patients or dosed by body weight.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brexpiprazole is not approved for use in pediatric patients or dosed by body weight.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brexpiprazole is not approved for use in pediatric patients or dosed by body weight.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Brexpiprazole is not approved for use in pediatric patients or dosed by body weight. |
| 5-7 kg | Not indicated | N/A | Brexpiprazole is not approved for use in pediatric patients or dosed by body weight. |
| 8-10 kg | Not indicated | N/A | Brexpiprazole is not approved for use in pediatric patients or dosed by body weight. |
| 11-15 kg | Not indicated | N/A | Brexpiprazole is not approved for use in pediatric patients or dosed by body weight. |
| 16-20 kg | Not indicated | N/A | Brexpiprazole is not approved for use in pediatric patients or dosed by body weight. |
Formulation
Purpose
Used for the treatment of schizophrenia, as an adjunctive (add-on) therapy for major depressive disorder (MDD), and for the treatment of agitation associated with dementia due to Alzheimer's disease.
Generic Name
BrexpiprazoleBranded Drug Names
Brexpiprazole is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.